Insider Selling: NovoCure (NASDAQ:NVCR) CFO Sells $85,343.72 in Stock

NovoCure Limited (NASDAQ:NVCR) CFO Christoph Brackmann sold 6,412 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $13.31, for a total value of $85,343.72. Following the sale, the chief financial officer directly owned 182,842 shares in the company, valued at approximately $2,433,627.02. This trade represents a 3.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

NovoCure Trading Down 8.4%

Shares of NVCR stock opened at $13.04 on Friday. NovoCure Limited has a twelve month low of $9.82 and a twelve month high of $21.55. The stock’s fifty day simple moving average is $12.74 and its 200 day simple moving average is $12.72. The company has a quick ratio of 1.50, a current ratio of 2.90 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $1.48 billion, a P/E ratio of -10.69 and a beta of 0.71.

NovoCure (NASDAQ:NVCR) last posted its earnings results on Thursday, February 26th. The medical equipment provider reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.19. NovoCure had a negative return on equity of 39.11% and a negative net margin of 20.79%.The firm had revenue of $174.35 million during the quarter, compared to the consensus estimate of $174.40 million. During the same period last year, the company earned ($0.61) earnings per share. The business’s quarterly revenue was up 8.2% on a year-over-year basis. As a group, sell-side analysts predict that NovoCure Limited will post -1.3 EPS for the current fiscal year.

Hedge Funds Weigh In On NovoCure

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Empowered Funds LLC bought a new stake in NovoCure in the fourth quarter valued at approximately $33,000. SJS Investment Consulting Inc. bought a new position in NovoCure during the 3rd quarter worth approximately $41,000. Kestra Advisory Services LLC acquired a new position in shares of NovoCure in the 4th quarter worth approximately $49,000. Larson Financial Group LLC boosted its stake in shares of NovoCure by 662.1% in the 3rd quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock valued at $53,000 after purchasing an additional 3,562 shares during the last quarter. Finally, Headlands Technologies LLC bought a new stake in shares of NovoCure in the 2nd quarter valued at $88,000. 84.61% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about NovoCure

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Q4 results beat EPS expectations (reported ($0.22) vs. ($0.41) est.) and revenue rose ~8.2% year?over?year — a fundamental positive that supports a recovery narrative and gives analysts a basis for higher targets. MarketBeat NVCR coverage
• Positive Sentiment: Some sell?side firms remain constructive (e.g., HC Wainwright raised its target and several analysts maintain Buy ratings), providing upside scenarios if clinical/commercial momentum continues. Analyst notes (MarketBeat)
• Neutral Sentiment: Brokerage consensus is an overall “Hold,” signaling limited near?term conviction for a sustained re?rating despite divergent analyst targets. NovoCure receives average “Hold” rating
• Neutral Sentiment: High institutional ownership (~84.6%) concentrates share control; that reduces free float but means large insider blocks can have outsized market impact when sold. Institutional holdings (MarketBeat)
• Neutral Sentiment: Minor individual insider sale by Michal Nath Puri (1,100 shares) is immaterial alone but contributes to the overall recent selling narrative. InsiderTrades alert
• Negative Sentiment: Chairman William F. Doyle sold a large block (71,887 shares, ?$933k), trimming his stake by ~18% — a substantial single insider sale that markets typically read as negative signaling. SEC filing: Doyle sale
• Negative Sentiment: Multiple senior executives (COO Mukund Paravasthu, CEO Frank Leonard, CFO Christoph Brackmann and others) executed notable sales in the same window — an aggregated pattern that likely amplified selling pressure and contributed to intraday weakness. SEC filings: Executive sales summary

Wall Street Analysts Forecast Growth

Several research firms recently commented on NVCR. HC Wainwright lifted their target price on shares of NovoCure from $47.00 to $49.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Weiss Ratings restated a “sell (e+)” rating on shares of NovoCure in a research report on Thursday, January 22nd. Evercore set a $20.00 price target on shares of NovoCure in a research note on Monday, January 5th. Finally, Wedbush reiterated a “neutral” rating and set a $18.00 price target on shares of NovoCure in a report on Thursday, January 15th. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $26.93.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.